Use of ciprofloxacin in patients undergoing transurethral prostatic surgery.
The efficacy of a short (Group I) and a prolonged (Group II) course with ciprofloxacin was assessed in patients undergoing transurethral prostatic resection and compared with that of controls without antibiotic (Group III). Both regimens significantly reduced the frequency of post-operative bacteriuria (p less than 0.01) and of severe infectious complications (p = 0.004) compared to the controls. Both regimens were equally effective in preventing peri-operative and post-operative acquisition of bacteriuria in patients without bacteriuria at surgery. In patients with bacteriuria before surgery, bacteriuria was found post-operatively in 35% in Group I and in 9% in Group II (p = 0.012), but in 82% of the patients in Group III. Ciprofloxacin inhibited all but 7 of 176 bacterial strains at an MIC of less than or equal to 1 microgram/ml. Given orally, ciprofloxacin is a valuable alternative antimicrobial for use in conjunction with transurethral prostatic resection. A short course is sufficient for prophylaxis, and adequate therapy is achieved with a prolonged regimen.
Department of Urology, University of Lund, Malmö General Hospital, Sweden.
S
S
Hellsten
A
A
Forsgren
T
T
Björk
M
M
Grabe
D001424:Bacterial Infections / Q000382:microbiology / Q000517:prevention & control*; D001437:Bacteriuria / Q000382:microbiology / Q000517:prevention & control; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D011292:Premedication; D011468:Prostatectomy / Q000379:methods*; D014552:Urinary Tract Infections / Q000382:microbiology / Q000517:prevention & control*
D002939:Ciprofloxacin